Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Prosthesis, ankle, uncemented, non-constrained

PMA Number: P050050 · 2024-03-13

ApplicantDjo Global
Decision Date2024-03-13
PMA NumberP050050
Product CodeNTG
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeOR

Device Summary

Prosthesis, ankle, uncemented, non-constrained is the device name listed in this FDA 510(k) record. The listed applicant is Djo Global. It received FDA 510(k) clearance on 2024-03-13. The device is classified under product code NTG. It was reviewed by the OR advisory panel.

Frequently Asked Questions

What is the Prosthesis, ankle, uncemented, non-constrained?

Prosthesis, ankle, uncemented, non-constrained is a medical device that received FDA 510(k) clearance on 2024-03-13. The listed applicant is Djo Global.

When did Prosthesis, ankle, uncemented, non-constrained receive FDA 510(k) clearance?

The clearance date for Prosthesis, ankle, uncemented, non-constrained can be found in the official FDA records.

Who is the listed applicant for Prosthesis, ankle, uncemented, non-constrained?

The FDA 510(k) record lists Djo Global as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Prosthesis, ankle, uncemented, non-constrained?

The FDA product code for Prosthesis, ankle, uncemented, non-constrained is NTG.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑